Releuko

Monitor blood, including CBCs, differentials, and platelets, before and during therapy (myelosuppressive chemotherapy: monitor twice weekly; BMT: frequently after transplant; SCN: during initial 4 weeks of therapy and during 2 weeks after dose adjustment). Discontinue if post nadir absolute neutrophil count (ANC) reaches >10,000/mm³ for patients receiving myelosuppressive chemotherapy; other indications: see full labeling. Monitor for splenomegaly/splenic rupture and for acute respiratory distress syndrome (ARDS); discontinue if ARDS occurs. Confirm diagnosis and do appropriate pretreatment hematological workup in SCN. Sickle cell disease: may cause severe sickle cell crisis (discontinue if occurs). Glomerulonephritis. Monitor for MDS/AML in those with severe chronic neutropenia, breast or lung cancer. Monitor for aortitis; discontinue if suspected. Avoid simultaneous use with chemo and radiation therapy. Permanently discontinue if serious allergic reactions occur. Possible transient (+) bone imaging changes in nuclear imaging. Pregnancy. Nursing mothers.